Trial Profile
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Acronyms KEYNOTE-017
- Sponsors Merck & Co
- 17 Mar 2022 Status changed from active, no longer recruiting to completed.
- 17 Oct 2019 Status changed from completed to active, no longer recruiting.
- 12 Sep 2019 Status changed from active, no longer recruiting to completed.